ARV-393 zaloblideg Updated Nov 3
The next hard catalyst is the initial Phase 1 monotherapy dose escalation data for ARV-393, submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026). Positive safety and early efficacy signals could re-rate the stock from near its 52-week low; any safety or tolerability concerns would be a setback for the BCL6 degrader program. A second data readout is expected in mid-2027.
- ARV-393 is a first-in-class oral PROTAC BCL6 degrader targeting an undruggable oncogenic driver in non-Hodgkin lymphoma, with strong preclinical data showing tumor regressions across multiple DLBCL models. Initial Phase 1 monotherapy data will be presented at ASH (Dec 12-15, 2026), a major medical conference, providing the first clinical proof-of-concept. Arvinas has $558.9M in cash (runway into H2 2028) and a diversified pipeline including the approved VEPPANU (vepdegestrant), reducing single-asset risk. Analyst consensus is positive: 13 Buy/Strong Buy vs 1 Sell, with a mean price target of $14.54 (93% upside from $7.52).
- ARV-393 is still in Phase 1 dose escalation with no clinical efficacy data yet; early-stage readouts often fail to translate. Competitor BMS-986458 (Bristol Myers Squibb) is also a BCL6 degrader in Phase 1/2, potentially beating ARV-393 to market with deeper pockets. Arvinas stock trades near its 52-week low ($6.74) and fell ~5.7% on Q3 earnings day, reflecting limited market enthusiasm for the early pipeline. The company has an approved product (vepdegestrant) but out-licensed it to Rigel, capping upside from that asset.